Archer Materials, a semiconductor company advancing the quantum technology and medical diagnostics industries, has signed an agreement with UK graphene-based electronics company Paragraf to advance development of Archer’s Biochip potassium ion sensor for testing of chronic kidney disease.
The agreement will be in two stages, with each stage of work to be carried out over three months at a total estimated cost of AU$450,000 or £222,000.
The partnership will accelerate technical progress towards meeting the blood potassium sensing target product profile (TPP) using a gFET. Work performed by Paragraf with Archer will complement the activities ongoing in Sydney.
Archer Materials, a semiconductor company advancing the quantum technology and medical diagnostics industries, has signed an agreement with UK graphene-based electronics company Paragraf to advance development of Archer’s Biochip potassium ion sensor for testing of chronic kidney disease. The agreement will be in two stages, with each stage of work to be carried out over three months at a total estimated cost of AU$450,000 or £222,000.The partnership will accelerate technical progress towards meeting the blood potassium sensing target product profile (TPP) using a gFET. Work performed by Paragraf with Archer will complement the activities ongoing in Sydney.
Read More Graphene-Info – Graphene industry portal












